COVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time
- 28 December 2024
- journal article
- letter
- Published by Springer Nature in Rheumatology International
- Vol. 45 (1) , 1-2
Abstract
We discuss the paper recently published in Rheumatology Internationa. This article reflects on the prevalence of autoimmune rheumatic diseases (ARD) during the COVID-19 pandemic (2020–2023) and compares the same with the pre-pandemic period (2016–2019). We assume that SARS-CoV-2 triggers ARD. This study concerns the 10 million population of Greece, and this work convincingly confirms our hypothesis. Besides, four large cohort studies have demonstrated an increased incidence of autoimmune diseases after surviving COVID-19. Compared to the prepandemic period, all ARD increased, and RA growth in the index study reached a level of more than 20% during the pandemic. A similar trend was observed in our report covering four Central Asian republics, namely Kazakhstan, Kyrgyzstan, Uzbekistan, and Tajikistan. The alarming growth of ARDs due to the consequences of the pandemic can still be predicted for the coming years. Healthcare professionals worldwide should be aware of this hypothesis to plan their COVID-19, long COVID, and ARD diagnostic and therapeutic strategies. We agree with the authors of the index article that more resources and research studies are warranted to optimize the diagnosis and treatment of ARDs in this challenging time.Keywords
This publication has 12 references indexed in Scilit:
- Increased prevalence of inflammatory arthritis, systemic lupus erythematosus and systemic sclerosis, during 2020–2023 versus 2016–2019 in a Nation-Wide Cohort StudyRheumatology International, 2024
- Increasing autoimmune rheumatic diseases as a consequence of the COVID‐19 pandemic: A hypothesis or fact?International Journal of Rheumatic Diseases, 2023
- Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19JAMA Network Open, 2023
- Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021The Lancet Rheumatology, 2023
- Long COVID: the time has come for globally acceptable definitionsRheumatology International, 2023
- Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort studyClinical Rheumatology, 2023
- Osteonecrosis amid the COVID-19 pandemicRheumatology International, 2023
- Long COVID in autoimmune rheumatic diseasesRheumatology International, 2023
- Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort studyeClinicalMedicine, 2023
- The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and preventionCurrent Opinion in Immunology, 2022